Highest-materiality recent filing
Greenland Mines enters agreement to acquire Neo North Star for $35M in cash and stock
Total consideration of $35M: $20M cash and $15M in newly issued GRML shares valued at 20-day VWAP.
Greenland Mines gets 180-day Nasdaq bid price compliance extension to Sep 14, 2026
Nasdaq granted additional 180-day extension through September 14, 2026 to regain $1 bid compliance.
Acquisition of Greenland Mines closed March 4, 2026; consideration is convertible preferred equity subject to shareholder approval.
Merger consideration: 47,000 Series C Preferred shares; each convertible into 42,554 common shares after stockholder approval.
Acquisition of Greenland Mines Corp. for convertible preferred stock; on conversion GMC holders get ~93% of fully diluted shares.
Klotho Neurosciences closes $7.75M private placement of 34.5M shares and warrants
Gross proceeds of ~$7.75M from 34,551,939 shares and warrants for same number of shares.
Klotho Neurosciences raises ~$7.75M through sale of 34.55M shares and warrants at $0.2243/share
Issued 34,551,939 shares at $0.2243 per share to 10 investors, raising approximately $7.75M.
Klotho Neurosciences raises ~$15M via sale of Series C convertible preferred stock to Sigma9 Capital
Sold 3,400 shares of Series C Preferred at $4,400/share to Sigma9 Capital Ltd for total proceeds of ~$15.0M.
Klotho Neurosciences receives Nasdaq delisting notice for bid price non-compliance
Received Nasdaq notice on Sept 19, 2025 for failing minimum bid price of $1 for 30 consecutive business days.
Klotho Neurosciences enters exclusive global gene therapy license with AAVnerGene
Exclusive global rights to AAVnerGene's AAVone platform for three gene therapy programs: KLTO-101, KLTO-202, KLTO-303.
Klotho regains Nasdaq bid price and equity compliance; phase-down to Capital Market approved
Regained compliance with Nasdaq minimum $1.00 bid price and $2.5M stockholders' equity requirements.
FDA grants Orphan Drug Designation for Klotho's KLTO-202 to treat ALS
FDA granted Orphan Drug Designation for KLTO-202 (s-KL-AAV.myo) for ALS.
KLTO-202 gene therapy manufacturing underway; process development & manufacturing expected to take approx. 8 months.
Klotho Neurosciences raises over $11M, retires all debt, exceeds Nasdaq equity requirement
Raised $11M+ from warrant exercises over June 8-13, 2025; Chardan acted as exclusive financial advisor.
Klotho Neurosciences reprices warrants to $1.35, corrects June 5 stock sale to 6.25M shares
Warrant exercise price reduced to $1.35 for period June 10-20, 2025; otherwise reverts to $3.49.
Pre-clinical study shows s-KL protein increased lifespan 20% in mice; company holds exclusive license for s-KL patents from UAB/ICREA.
Klotho Neurosciences receives Nasdaq bid price non-compliance notice; response due April 22
Received Nasdaq notice on April 15, 2025, for continued failure to meet minimum $1 bid price (Rule 5450(a)(1)).
Klotho Neurosciences receives Nasdaq extension to Aug 13, 2025 for listing compliance
Nasdaq Hearing Panel granted extension until August 13, 2025 to regain compliance with MVPHS and MVLS rules.
Klotho to acquire SkyBell doorbell unit for 90% of its fully diluted stock
Klotho to acquire SB Security Holdings (SkyBell video doorbell) for 90% of its fully diluted common stock.
Klotho Neurosciences receives Nasdaq delisting notice; appeals hearing requested
Received delisting notice on Feb 14, 2025 for failing MVPHS and MVLS requirements under Nasdaq Listing Rules 5450(b)(2)(C) and (b)(2)(A).
Klotho Neurosciences raises $2M via convertible notes and warrants with institutional investor
Aggregate purchase price of $2M for convertible notes (principal $2,173,914) and warrants (4M shares).
Klotho Neurosciences enters $1.2M convertible note with 20% OID, 2M inducement shares
Principal $1.2M, 20% original-issue discount, unsecured, no interest, matures Dec 4, 2025.
Klotho Neurosciences dismisses auditor Yusufali after PCAOB disqualification; names BCRG Group
Terminated Yusufali & Associates as auditor on Oct 26, 2024, due to PCAOB disqualification.
Received Nasdaq notice on Oct 15, 2024 for failing to maintain $1 minimum bid price for 30 consecutive business days.
ANEW Medical receives Nasdaq delisting notices for MVPHS and MVLS non-compliance
Nasdaq notified ANEW Medical on Aug 16, 2024 for failing MVPHS ($15M) and MVLS ($50M) requirements.
ANEW Medical appoints CFO LeBlanc ($325k base) and COO Moriarty ($300k base) effective Aug 15
Jeffrey LeBlanc appointed CFO effective Aug 15, 2024; 3-year term, base salary $325k, initial 100k shares + 400k shares vesting over 2 years.
Redwoods Acquisition Corp. closes merger with ANEW Medical, renamed ANEW Medical, Inc.
Business combination closed June 21, 2024; combined company now named ANEW Medical, Inc. (ticker: WENA).
Redwoods SPAC files restated ANEW Medical audited financials; prior auditor barred by SEC
ANEW Medical net loss $707K in FY2023 vs $599K in FY2022; accumulated deficit $3.9M.
RWOD corrects redemption price to $10.78; signs Meteora backstop for ANEW merger
Redemption price corrected to $10.78 per share (trust balance $18.99M; net of $770k tax withdrawal).
RWOD enters Forward Purchase with Meteora for up to 1M shares; notes 1.59M redemption requests
Forward Purchase Agreement with Meteora entities for up to 1,000,000 shares at $10.00 to support ANEW Medical merger.
Redwoods Acquisition secures non-redemption agreement for up to 360K shares amid 1.59M redemptions
Redemption requests total 1,589,776 shares as of May 8; only 170,418 shares will remain outstanding post-redemption.
Redwoods Acquisition stockholders approve ANEW Medical merger; 1.74M shares redeemed
All six proposals passed with strong support; business combination adoption received 4,185,975 for, 3,052 against.
On November 19, 2024, the Board of Directors of Klotho Neurosciences, Inc. (the “Company”) appointed Riad El-Dada to the Board of Director to fill a vacancy on the Board of Directors with a term expiring at the Company’s next Annual Meeting of Stockholders.
On August 25, 2024, Edward Cong Wang resigned as a member of the Company’s Board of Directors.
On August 15, 2024, Jeffrey LeBlanc was appointed as the Company’s Chief Financial Officer.
Also on August 15, 2024, Peter Moriarty was appointed as the Company’s Chief Operating Officer.
On July 30, 2024, Edward Cong Wang, the Company’s interim Chief Financial Officer, resigned from that position.
Max materiality 0.95 · Median 0.62 · Most common event other_material